New Haven biotech Arvinas reports it has begun its first human trial on a groundbreaking drug that aims to fight prostate cancer by inducing the body to attack and remove a protein linked to the disease.
Arvinas says it has begun dosing patients in a Phase 1 study of its drug ARV-110 for the treatment of metastatic castration-resistant prostate cancer. more